RPGL.F Stock Overview
An investment holding company, holds investments in the healthcare and life sciences sectors in Europe, the United States, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Regent Pacific Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.0008 |
| 52 Week High | HK$0.068 |
| 52 Week Low | HK$0.0008 |
| Beta | 1.04 |
| 11 Month Change | 0% |
| 3 Month Change | -98.40% |
| 1 Year Change | -99.00% |
| 33 Year Change | n/a |
| 5 Year Change | -99.73% |
| Change since IPO | -99.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| RPGL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 2.0% |
| 1Y | -99.0% | 13.7% | 32.4% |
Return vs Industry: RPGL.F underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: RPGL.F underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| RPGL.F volatility | |
|---|---|
| RPGL.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RPGL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RPGL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 17 | Jamie Alexander Gibson | www.regentpac.com |
Regent Pacific Group Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in Europe, the United States, and the Asia Pacific. The company operates through Biopharma and Corporate Investment segments. It is involved in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels.
Regent Pacific Group Limited Fundamentals Summary
| RPGL.F fundamental statistics | |
|---|---|
| Market cap | US$11.60m |
| Earnings (TTM) | -US$15.47m |
| Revenue (TTM) | US$51.00k |
227.4x
P/S Ratio-0.7x
P/E RatioIs RPGL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPGL.F income statement (TTM) | |
|---|---|
| Revenue | US$51.00k |
| Cost of Revenue | US$1.22m |
| Gross Profit | -US$1.17m |
| Other Expenses | US$14.30m |
| Earnings | -US$15.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.068 |
| Gross Margin | -2,288.24% |
| Net Profit Margin | -30,335.29% |
| Debt/Equity Ratio | -18.0% |
How did RPGL.F perform over the long term?
See historical performance and comparison